International Braz j Urol 2023

1 papers

Top Research Directions

The 3 research directions with International Braz j Urol 2023 papers, ranked by paper count, next to 2020. Share is the fraction of the edition’s papers in the direction.

#Direction20232020Share 2023Share 20202020 rank
1Biparametric MRI for Prostate Cancer Screening10100.0%0.0%—
2Identifying Independent Risk Factors with Multivariable Logistic Regression10100.0%0.0%—
3The Hidden Pitfalls of Single Institution Datasets10100.0%0.0%—

Download all directions as CSV

Institutions

Institutions credited by International Braz j Urol 2023 papers: a paper credits every institution named in its affiliations, once. 3 institutions share 1 credited papers.

#InstitutionPapersShare20202020 rank
102jwb5s28 1100.0%0—
2Chinese Academy of Medical Sciences & Peking Union Medical College 1100.0%0—
3Peking University 1100.0%0—

Download all institutions as CSV

About this data

Papers. International Braz j Urol 2023 lists 1 papers on Lacuna, duplicate versions counted once; rejected and withdrawn submissions are left out.

Directions. Directions are Lacuna’s clustering of the concept elements extracted from each paper, so a paper can belong to several and direction counts add up to more than the paper count. A direction’s share is its papers divided by the edition’s papers. Comparisons with 2020 use shares, since the edition went from 1 to 1 papers.

Institutions. A paper credits each institution named in its affiliations, resolved to a ROR record, once. 1 of 1 papers (100.0%) credit at least one institution and are the base for institution shares; the rest have no resolved affiliation yet.

Data. Counts come from Lacuna’s data build of 2026-11-18 and change as papers are added. Tables as CSV: directions · institutions. Cite as: Lacuna, “International Braz j Urol 2023”, https://lacuna.tiptreesystems.com/venue/international-braz-j-urol/2023.

Papers

Title
Is it necessary for all patients with suspicious lesions undergo systematic biopsy in the era of MRI-TRUS fusion targeted biopsy?